Editas Medicine, Inc. Common Stock (EDIT) — Analysis Summary
Editas Medicine, Inc. Common Stock (EDIT) has a market cap of $512.56M with year-over-year revenue growth of +25.4%. Net margin stands at -395.0%. The stock trades at a P/E ratio of -4.7.
Key Takeaways
- Revenue changed +25.4% year-over-year
- Net margin of -395.0%
- P/E ratio of -4.7
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, EDIT posted revenue growth of +25.4% and trades at a P/E of -4.7.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.